Carolyn E. Taylor - 12 May 2026 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Reporting relationship: Director
Issuer ticker: TNXP
Reported as of: 12 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 May 2026, 17:41:51 UTC
Prior SEC filing: 21 Aug 2025
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jessica Morris, Attorney-in-Fact

Key filing fact

Carolyn E. Taylor filed Form 4 for Tonix Pharmaceuticals Holding Corp. (TNXP) on 14 May 2026.

Key facts

This page summarizes Carolyn E. Taylor's Form 4 filing for Tonix Pharmaceuticals Holding Corp. (TNXP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 May 2026, 17:41.

Change

Previous filing in this sequence was filed on 21 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001875324 Primary reporting owner

Taylor Carolyn E.

Relationship: Director
Address: C/O TONIX PHARMACEUTICALS HOLDING CORP., 200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS
Signature: /s/ Jessica Morris, Attorney-in-Fact
Signature date: 14 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNXP transaction Derivative

Stock Option

Award

Transaction value
Shares: +22,700
Change %
Price: $0.000000^*
Shares after: 22,700
Date: 12 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,700
Exercise price: $13.28
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders.